Gallium-68 Gozetotide: A Radiopharmaceutical Agent for PET Imaging

Gallium-68 Gozetotide is a radiopharmaceutical agent used in Positron Emission Tomography (PET) imaging. PET is a non-invasive nuclear imaging technique that utilises radiotracers to create 3-D images of biological processes within the body. Ga-68 Gozetotide is a somatostatin receptor (SSTR) antagonist, which allows it to target and bind to SSTRs in various tumour types. This article provides an overview of the synthesis, properties, and applications of Gallium-68 Gozetotide in oncology.

Synthesis and Properties of Gallium-68 Gozetotide

Gallium-68 is a positron-emitting radioisotope with a half-life of 68 minutes. It is typically produced through a 68Ge/68Ga generator system, allowing radionuclide on-demand production. Gozetotide, a somatostatin analogue, is then radiolabelled with Ga-68 via a chelator, such as 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA). This results in the formation of Ga-68 Gozetotide.

Using Ga-68 as the radioisotope for PET imaging has several advantages, including its short half-life, which reduces radiation exposure to patients and staff, and its high positron yield, providing excellent image resolution.

Applications in Oncology of 68Ga Gozetotide

Gallium-68 Gozetotide PET imaging has emerged as an essential diagnostic tool in oncology, particularly for detecting and staging neuroendocrine tumours (NETs). NETs are a heterogeneous group of neoplasms originating from neuroendocrine cells distributed throughout the body. These tumours often overexpress somatostatin receptors, making them ideal targets for Ga-68 Gozetotide.

The high affinity of Ga-68 Gozetotide for SSTRs allows for detecting NETs with high sensitivity and specificity. This radiopharmaceutical agent has shown its ability to accurately identify primary and metastatic NETs, providing essential information for treatment planning.

Ga-68 Gozetotide PET imaging is also being investigated for its potential use in other malignancies, such as breast, prostate, and lung cancers, where SSTR expression is observed.

Advantages and Limitations of Gallium-68 Gozetotide

One of the main advantages of Ga-68 Gozetotide is its high target-to-background ratio, which results in improved lesion detection compared to other radiopharmaceuticals. Additionally, the short half-life of Ga-68 reduces the radiation burden on patients and enables rapid scanning times.

However, there are some limitations to the use of Ga-68 Gozetotide. As with any radiopharmaceutical, there is a risk of allergic reactions or adverse events related to the radiotracer. Furthermore, the production of Ga-68 requires specialised equipment and trained staff, which may limit its availability in some medical centres.


Gallium-68 Gozetotide has shown promise as a radiopharmaceutical agent for PET imaging in oncology, particularly for detecting and staging neuroendocrine tumours. Its high affinity for somatostatin receptors and excellent imaging properties make it a valuable tool in diagnosing and managing these malignancies. However, further research is needed to explore its full potential in the field of oncology and to expand its applications in other cancer types.

Tags: PET Radiotracer, Prostate Cancer, Radiopharmaceuticals
Open Medscience